Alpine Immune Sciences Announces Poster Presentation at 2020 Crohn's & Colitis Congress
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn's & Colitis Congress taking place January 23-25, 2020, in Austin, Texas.
Details of the presentation are as follows:
Presentation Title: ALPN-101, A First-In-Class Dual ICOS/CD28 Antagonist, Demonstrates Efficacy in Patient-Derived PBMC In Vitro and in an In Vivo T Cell Transfer Model of Chronic Inflammatory Bowel Disease (IBD)
Session Title: Animal Models: Pre-Clinical Treatment of Intestinal Inflammation
Dates and Times: Thursday, January 23, 2020, 7:00 ? 9:00 p.m. and Friday, January 24, 2020, 3:50 ? 4:20 p.m.
Presentation Location: Exhibit Hall 1, Austin Convention Center
Session Type: Poster Session
Poster Number: P156
An abstract of the presentation is available in the online planner section of the Crohn's & Colitis Congress website and in the Congress Mobile App.
About ALPN-101
ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDtm), and a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely-related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease, and multiple sclerosis, ALPN-101 demonstrates efficacy superior to agents blocking the CD28 ? CD80/86 or ICOS - ICOSL pathways alone.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients' lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.
OKX, a leading Web3 technology company, today added support for Runes, a new fungible token standard by Casey Rodarmor, a former Bitcoin developer and artist, following today's Bitcoin halving. With this addition, users can now create, mint, manage...
Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") , a California-based global shared intelligent electric mobility ecosystem company, today announced that it received a letter (the "Nasdaq Letter") from The Nasdaq Stock...
Genifi Inc. (formerly Prodigy Ventures Inc.) ("genifi" or the "Company") today announced its financial results for the three months and year ended December 31, 2023. As previously reported, the Company sold TCB Corporation ("Prodigy Labs") on...
Sabre Corporation ("Sabre") announced plans to host a live webcast of its 2024 Annual Meeting of Stockholders on April 24, 2024 at 10:30 a.m. ET. The webcast will be accessible by visiting the Investor Relations section of Sabre's website...
Illinois House Speaker Emanuel "Chris" Welch was unanimously recommended to serve as the new Proviso Township Committeeman in a meeting held Friday evening of the Executive Committee, replacing the late Karen Yarbrough....
Nium, the global leader in real-time, cross-border payments, and Asia's leading payments, banking, and capital markets research firm, Kapronasia, today launched "Breaking Borders: The Revolution of Real-Time Cross-Border B2B Payments in Asia" - a new...